BEVITAL AS

Transportation

Before shipment of samples several factors have to be considered to achieve optimal sample conditions, and to avoid sample thawing or loss during transportation.

1. Aliqoting and sample mixing

When sample for transportation and analysis is taken from a source vial, great care must be taken to ensure proper mixing of the content before pipetting. During freezing and thawing, gradients of serum/plasma components, in particular of albumin, are formed. Simple vortexing, in particular if the vial is full, may not be sufficient to generate a homogeneous solution. Therefore, repeated tilting of the vial with a small air bubble is recommended. Avoid foaming. Pipetting from vials that have solute gradients will affect analyte concentration to a variable extent. Albumin-bound biomarkers, like total homocysteine and total cysteine, are most seriously affected (up to 20 % difference).

2. Packing and organization

The samples must be placed in sufficient dry ice to keep them frozen for 4 – 5 days. Thus, a box with 6 – 800 samples should contain about 10 kg of dry ice. The samples should be placed in 1-2 mL vials with a screw cap, and clearly labelled with serial numbers, printed (not hand-written) on a label, which tolerates freezing. They must be placed and immobilized in boxes accommodating 100 vials, and sorted in a sequence which matches an accompanying excel data sheet with serial number and additional unequivocal identification. This excel file must be send to us by e-mail the day the parcel is dispatched.

3. Sample sequence

The samples are analyzed in the order provided on the excel sheet and according to the organization of the vials in the boxes used for transportation. If you have special requirements for the sequence of the analyses (paired cases and controls, randomization, longitudinal sampling, etc…), you have to organize your samples accordingly. Please contact us if you have questions concerning sample sequence organization.

4. Information

On a separate page, please also provide information on:
– the title of the project,
– matrix (plasma or serum)
– storage (duration and temperature)
– freezing and thawing cycles (number)
– sample volume (µL)
– number of samples
– vitamins and metabolites to be measured (platforms A-I)

5. Courier

The parcel must be marked with VALUE = 10 (USD or EURO), to avoid custom delay and extra cost.

Samples should be transported by a competent courier on dry ice:
– For US and other overseas shipments we recommend WORLD COURIER, which allows dry ice and guarantees refilling of dry ice if required. The company has local representatives in Norway, takes care of all paperwork and thereby avoids that the parcel is stuck in the customs office. WORLD COURIER is expensive, e.g. transportation of 1 item of 10 kg to/from USA costs about 1500€; 3 items about 2000 €.
– We have also used QUICK International for overseas shipment.
– For shipment within Europe we have used DHL, which after agreement allows dry ice, but does not refill ice; it is quick and not expensive. The company has local representative in Bergen. FedEx should be avoided, since this company does not transport with dry ice within Norway, and the shipment stops in Oslo.

The parcel should preferably be dispatched on a Monday, to avoid over weekend delay. At the day of transportation please notify Randi Mjelde Heimdal (randi.heimdal@bevital.no) or post@bevital.no about the day of shipment and AIR WAY BILL NUMBER. It is also recommended that you track your shipment during transportation, and notify us if samples are delayed.

Please sent the samples to:
Randi Mjelde Heimdal
Bevital AS
Frydenbøgården 5. etg.
Minde Allé 35
5068 Bergen, Norway

September 30, 2025
Scroll to Top

Per Christian Eriksen

Øivind

Per Magne Ueland has been Professor at the University of Bergen 1987-2018. He is one of the founders of Bevital AS and the scientific advisor in Bevital since 2023. His interests includes biomarkers related to nutrition, inflammation, ageing and life-style related chronic diseases. Per is committed to the development of precise, high-throughput mass spectrometry methods, tailored for metabolic profiling of biobank specimens from large cohorts.

Marit holds a degree in chemical engineering from Bergen Ingeniørhøyskole, which is now part of the Western Norway University of Applied Sciences. She works with quantitative analysis and method development on LC-MS/MS at the laboratory of Bevital AS.

Ove completed a bachelor’s degree in Biomedical Laboratory Sciences at the Western Norway University of Applied Sciences in Bergen. With extensive experience in method development and expertise in GC-MS/MS, he specializes in optimizing analytical techniques for research-focused studies. At Bevital, Ove is dedicated to advancing laboratory methods and workflows, contributing to innovative research through precise and reliable analytical solutions.

Lene holds a bachelor’s degree in Biomedical Laboratory Science from the Western Norway University of Applied Sciences, where she is also completing her master’s degree in Medical Laboratory Technology. At Bevital, she works with GC-MS/MS analyses, focusing on accurate and reliable testing of biological samples. With her strong laboratory background, Lene is committed to delivering high-quality results that support medical research.

Klaus holds a PhD in physics from the University of Münster in Germany. He has over three decades of experience in Time-of-Flight mass spectrometry. He leverages his extensive expertise to provide customers with cutting-edge MALDI-MS analysis and the newest Olink Proteomics services.

Adrian holds a PhD in diabetes research, along with bachelor’s and master’s degrees in biomedical science and public health, respectively. With over 20 years of experience in laboratory science, he leads high-precision metabolite analyses and method development at Bevital. His expertise centers on quantifying biomarkers, metabolite classes, and metabolic pathways related to nutrition, cardiovascular and neurodegenerative diseases, and cancer. Adrian is committed to advancing research quality and actively collaborates nationally and internationally, leveraging targeted metabolomics to support innovative, multidisciplinary research.

Statistical power is the probability that a statistical test will correctly reject a false null hypothesis (H0​) when a specific alternative hypothesis (H1​) is true. H0​ is the null hypothesis, which states there is no effect or no difference. H1​ is the alternative hypothesis, which states there is a real effect or difference. Alpha (α) is the probability of a Type I error (a false positive), which is the risk of incorrectly rejecting the H0​ when it is actually true. You set this value before the experiment, commonly at 0.05. Beta (β) is the probability of a Type II error (a false negative), which is the risk of failing to reject the H0​ when it is actually false.

Power is calculated as 1−β. Increasing power means you are decreasing the probability of making a Type II error.

Several factors can be adjusted to increase the power of a statistical test:

  • Effect Size: This is the magnitude of the difference you are trying to detect. A larger effect size is easier to detect, thus increasing power. 

  • Sample Size: The number of observations in a study. A larger sample size provides more information about the population, reducing the margin of error and increasing the power to detect a true effect.

  • Variation: Refers to the spread or standard deviation of the data within the population. Less variation makes it easier to distinguish a real effect from random noise, thereby increasing power.

  • Alpha (): Increasing the alpha level (e.g., from 0.05 to 0.10) also increases power, but at the cost of a higher risk of a Type I error. This trade-off is often undesirable.

562 entries « 28 of 29 »
541.

Refsum, H; Yajnik, C S; Gadkari, M; Schneede, J; Vollset, S E; Orning, L; Guttormsen, A B; Joglekar, A; Sayyad, M G; Ulvik, A; Ueland, P M

Hyperhomocysteinemia and elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian Indians Journal Article

In: Am J Clin Nutr, vol. 74, no. 2, pp. 233–241, 2001, ISSN: 0002-9165.

Abstract | Links | BibTeX

542.

Vollset, S E; Refsum, H; Tverdal, A; Nygård, O; Nordrehaug, J E; Tell, G S; Ueland, P M

Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study Journal Article

In: Am J Clin Nutr, vol. 74, no. 1, pp. 130–136, 2001, ISSN: 0002-9165.

Abstract | Links | BibTeX

543.

Ulvik, A; Evensen, E T; Lien, E A; Hoff, G; Vollset, S E; Majak, B M; Ueland, P M

Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum Journal Article

In: Am J Med Genet, vol. 101, no. 3, pp. 246–254, 2001, ISSN: 0148-7299.

Abstract | Links | BibTeX

544.

Chambers, J C; Ueland, P M; Wright, M; Doré, C J; Refsum, H; Kooner, J S

Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects Journal Article

In: Circ Res, vol. 89, no. 2, pp. 187–192, 2001, ISSN: 1524-4571.

Abstract | Links | BibTeX

545.

Guttormsen, A B; Ueland, P M; Kruger, W D; Kim, C E; Ose, L; Følling, I; Refsum, H

Disposition of homocysteine in subjects heterozygous for homocystinuria due to cystathionine beta-synthase deficiency: relationship between genotype and phenotype Journal Article

In: Am J Med Genet, vol. 100, no. 3, pp. 204–213, 2001, ISSN: 0148-7299.

Abstract | Links | BibTeX

546.

El-Khairy, L; Ueland, P M; Refsum, H; Graham, I M; and, S E Vollset

Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project Journal Article

In: Circulation, vol. 103, no. 21, pp. 2544–2549, 2001, ISSN: 1524-4539.

Abstract | Links | BibTeX

547.

Ueland, P M; Hustad, S; Schneede, J; Refsum, H; Vollset, S E

Biological and clinical implications of the MTHFR C677T polymorphism Journal Article

In: Trends Pharmacol Sci, vol. 22, no. 4, pp. 195–201, 2001, ISSN: 0165-6147.

Abstract | Links | BibTeX

548.

Nurk, E; Tell, G S; Nygård, O; Refsum, H; Ueland, P M; Vollset, S E

Plasma total homocysteine is influenced by prandial status in humans: the Hordaland Hhomocysteine Sstudy Journal Article

In: J Nutr, vol. 131, no. 4, pp. 1214–1216, 2001, ISSN: 0022-3166.

Abstract | Links | BibTeX

549.

Vollset, S E; Refsum, H; Ueland, P M

Population determinants of homocysteine Miscellaneous

2001, ISSN: 0002-9165.

Links | BibTeX

550.

Dekou, V; Whincup, P; Papacosta, O; Ebrahim, S; Lennon, L; Ueland, P M; Refsum, H; Humphries, S E; Gudnason, V

The effect of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British regional heart study Journal Article

In: Atherosclerosis, vol. 154, no. 3, pp. 659–666, 2001, ISSN: 0021-9150.

Abstract | Links | BibTeX

551.

Ueland, P M; Nygård, O; Vollset, S E; Refsum, H

The Hordaland Homocysteine Studies Journal Article

In: Lipids, vol. 36 Suppl, pp. S33–S39, 2001, ISSN: 0024-4201.

Abstract | Links | BibTeX

552.

Bolann, B J; Solli, J D; Schneede, J; Grøttum, K A; Loraas, A; Stokkeland, M; Stallemo, A; Schjøth, A; Bie, R B; Refsum, H; Ueland, P M

Evaluation of indicators of cobalamin deficiency defined as cobalamin-induced reduction in increased serum methylmalonic acid Journal Article

In: Clin Chem, vol. 46, no. 11, pp. 1744–1750, 2000, ISSN: 0009-9147.

Abstract | BibTeX

553.

Chambers, J C; Ueland, P M; Obeid, O A; Wrigley, J; Refsum, H; Kooner, J S

Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine Journal Article

In: Circulation, vol. 102, no. 20, pp. 2479–2483, 2000, ISSN: 1524-4539.

Abstract | Links | BibTeX

554.

Louwman, M W; van Dusseldorp, M; van de Vijver, F J; Thomas, C M; Schneede, J; Ueland, P M; Refsum, H; van Staveren, W A

Signs of impaired cognitive function in adolescents with marginal cobalamin status Journal Article

In: Am J Clin Nutr, vol. 72, no. 3, pp. 762–769, 2000, ISSN: 0002-9165.

Abstract | Links | BibTeX

555.

Hustad, S; Ueland, P M; Vollset, S E; Zhang, Y; Bjørke-Monsen, A L; Schneede, J

Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism Journal Article

In: Clin Chem, vol. 46, no. 8 Pt 1, pp. 1065–1071, 2000, ISSN: 0009-9147.

Abstract | BibTeX

556.

Ueland, P M; Refsum, H; Beresford, S A; Vollset, S E

The controversy over homocysteine and cardiovascular risk Journal Article

In: Am J Clin Nutr, vol. 72, no. 2, pp. 324–332, 2000, ISSN: 0002-9165.

Abstract | Links | BibTeX

557.

Nexo, E; Engbaek, F; Ueland, P M; Westby, C; O'Gorman, P; Johnston, C; Kase, B F; Guttormsen, A B; Alfheim, I; McPartlin, J; Smith, D; Møller, J; Rasmussen, K; Clarke, R; Scott, J M; Refsum, H

Evaluation of novel assays in clinical chemistry: quantification of plasma total homocysteine Journal Article

In: Clin Chem, vol. 46, no. 8 Pt 1, pp. 1150–1156, 2000, ISSN: 0009-9147.

Abstract | BibTeX

558.

Mudd, S H; Finkelstein, J D; Refsum, H; Ueland, P M; Malinow, M R; Lentz, S R; Jacobsen, D W; Brattström, L; Wilcken, B; Wilcken, D E; Blom, H J; Stabler, S P; Allen, R H; Selhub, J; Rosenberg, I H

Homocysteine and its disulfide derivatives: a suggested consensus terminology Journal Article

In: Arterioscler Thromb Vasc Biol, vol. 20, no. 7, pp. 1704–1706, 2000, ISSN: 1079-5642.

Links | BibTeX

559.

Vollset, S E; Refsum, H; Irgens, L M; Emblem, B M; Tverdal, A; Gjessing, H K; Monsen, A L; Ueland, P M

Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study Journal Article

In: Am J Clin Nutr, vol. 71, no. 4, pp. 962–968, 2000, ISSN: 0002-9165.

Abstract | Links | BibTeX

560.

Lien, E A; Nedrebø, B G; Varhaug, J E; Nygård, O; Aakvaag, A; Ueland, P M

Plasma total homocysteine levels during short-term iatrogenic hypothyroidism Journal Article

In: J Clin Endocrinol Metab, vol. 85, no. 3, pp. 1049–1053, 2000, ISSN: 0021-972X.

Abstract | Links | BibTeX

562 entries « 28 of 29 »

Olink Proteomics

Please fill out the fields below (*required).
We will respond to you ASAP.
Thank you!

Customized analyses

Please fill out the fields below (*required).
We will reply to you soon for a detailed project discussion.
Thank you for reaching out to Bevital!

Mix-and-Match

Please fill out the fields below (*required).
We will respond to you as soon as possible.

Ready-to-Run

Please fill out the fields below (*required).
We will respond ASAP.
Thank you!

Thanks for joining!

Get updates about new method developments, publications and comming events.